The potential acquisition of Syqe Medical by Phillip Morris represents a significant strategic move for the tobacco giant, signaling its entry into the flourishing marijuana industry. With an initial investment of $130 million to support Syqe’s FDA approval process, followed by a possible $650 million acquisition, this deal can potentially make Syqe one of the largest cannabis companies globally. Moreover, Syqe’s innovative inhaler, utilizing raw cannabis inflorescence, could secure FDA approval, positioning the company as a trailblazer in the medical cannabis sector.
Cannabis grower and edibles pioneer Maya Elisabeth makes the case that your sourdough starter is…
Berlin police are warning residents after receiving reports that suspected drug samples were being left…
Cannabis culture survived through decentralized human connection. Its future depends on whether the people building…
For years, the cannabis world has treated "the entourage effect" like settled science, a comforting…
After five years, two applications, six figures in expenses, and a maze of shifting rules,…
This article was originally published in 2023. From the hash and honey oil of the…